FSL-1 TFA, a bacterial-derived toll-like receptor 2/6 (TLR2/6) agonist, enhances resistance to experimental HSV-2 infection. FSL-1 TFA induces MMP-9 production through TLR2 and NF-κB/AP-1 signaling pathways in monocytic THP-1 cells.
性状
Solid
IC50 & Target[1][2]
TLR2 TLR6
体外研究(In Vitro)
FSL-1 significantly reduces HSV-2 replication in human vaginal epithelial cells (EC).FSL-1 induces significant resistance to experimental genital HSV-2 infection through elaboration of a specific cytokine response profile.FSL-1 (50 ng/mL, 24 hours) induces MMP-9 expression at both mRNA and protein levels in human monocytic THP-1 cells.FSL-1 activates the MAP kinase/NF-κB signaling pathway. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
FSL-1 application significantly protectes against genital HSV-2 challenge in mice. has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: Female Swiss-Webster mice (weighing 20-25 g)
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
-80°C
SequenceShortening
S-(2, 3-Bispalmitoyloxypropyl)-CGDPKHPKSF
参考文献
[1]. William A Rose 2nd, et al. FSL-1, a bacterial-derived toll-like receptor 2/6 agonist, enhances resistance to experimental HSV-2 infection. Virol J. 2009 Nov 10;6:195.[2]. Cathryn J Kurkjian,et al. The Toll-Like Receptor 2/6 Agonist, FSL-1 Lipopeptide, Therapeutically Mitigates Acute Radiation Syndrome. Sci Rep. 2017 Dec 11;7(1):17355.
溶解度数据
In Vitro: H2O : 50 mg/mL (28.09 mM; Need ultrasonic)配制储备液